Similarly, for progression-free interval (PFI), CCNF was significantly associated with worse clinical outcomes in KIRC, LIHC, KIRP, LGG, ACC, PAAD, prostate adenocarcinoma (PRAD), and MESO, while acting as a protective factor in COAD (Figure S4). This evidence concerns the gene CCNF and prostate adenocarcinoma.